Multicentre clinical evaluation of the COBAS CORE CEA, CA 125 II and PSA tumor marker assays. 1996

X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
Department of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinic Provincial, Barcelona, Spain.

The aim of our study was to evaluate the clinical usefulness of the tumor markers CEA, CA 125 and PSA using the COBAS CORE system from Roche Diagnostic Systems. Our results demonstrate that determination of these markers on the COBAS CORE immunoassay analyser provides the performance required for routine use in clinical practice. The results obtained in this clinical trial validate the correlation with disease extension, a characteristic that defines and determines the clinical utility of the tumor markers. We also conclude that learning to operate the COBAS CORE system is simple, as is management of the system through the user-friendly software.

UI MeSH Term Description Entries
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
October 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
January 1996, European journal of gynaecological oncology,
X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
January 1998, Wiener klinische Wochenschrift,
X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
January 2006, Advances in therapy,
X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
June 1995, Schweizerische medizinische Wochenschrift,
X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
January 1999, Anticancer research,
X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
January 1998, Annales de biologie clinique,
X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
November 1996, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
October 2010, Revista espanola de cardiologia,
X Filella, and A M Ballesta, and M Fox, and H Mitchell, and R Molina, and P Pürstner, and H Thome
January 1995, International journal of cancer,
Copied contents to your clipboard!